• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconBiotech

Biotech

Page 15 of 19
Key Speakers At The Hedge Funds Summit
FinanceOlive Garden Investor’s New Stock Pick Is This Biotech
By ReutersApril 8, 2016
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange
HealthSamsung’s Drug Group Is Taking AbbVie to Court in Biotech Copycat Push
By ReutersApril 4, 2016
The U.S. and Europe Could Save $110 Billion With Copycat Biotech Drugs
HealthThe U.S. and Europe Could Save $110 Billion With Copycat Biotech Drugs
By ReutersMarch 29, 2016
Kim Le, a research associate for FivePrime Therapeutics, wor
HealthAffymetrix Rejects Rival Bid, Supports Thermo Fisher Merger
By ReutersMarch 20, 2016
503920324
FinanceThe Hottest IPO of 2016 Is Crashing
By Sy MukherjeeMarch 9, 2016
Alaska Now Has a $1 Billion Stake in This Biotech Startup
FinanceAlaska Now Has a $1 Billion Stake in This Biotech Startup
By Sy MukherjeeMarch 3, 2016
Dow Starts Week Off With Sharp Gains, Closing Over 250 Points Higher
FinanceHere’s Why Biotech Stocks Are Soaring
By ReutersMarch 1, 2016
NASDAQ Climbs Above 5000 Points For First Time In 15 Years
FinanceThese Companies Just Busted the IPO Drought
By ReutersFebruary 3, 2016
Symbolic - biotechnology - genetic engineering
TechGuess What This Early Skype Investor Is Betting on Now
By ReutersFebruary 2, 2016
Key Speakers At The Stanford Institute For Economic Policy Research Forum
LeadershipGilead CEO John Martin Is Stepping Down After 20 Years
By Jen WiecznerJanuary 29, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceBiotech Stocks Crashed and Nobody Knows Why
By Jen WiecznerJanuary 28, 2016
Biosimilars Are Coming After Big Pharma’s Bottom Line
HealthBiosimilars Are Coming After Big Pharma’s Bottom Line
By Laura LorenzettiJanuary 12, 2016
AbbVie Inc. To Buy Shire For $54.8 Billion
HealthShire-Baxalta $32 Billion Merger Talks Said to Advance
By Michal AddadyJanuary 3, 2016
Biotech’s Insane Year
HealthBiotech’s Insane Year
By Laura LorenzettiDecember 31, 2015
Inside of a Gilead Sciences Lab
FinanceIsis Pharmaceuticals Changes Its Name After Terrorists Attack Stock Price
By Jen WiecznerDecember 18, 2015
1...
  • 13
  • 14
  • 15
  • 16
  • 17
...19
Most Popular
Economy
Jerome Powell says the $39 trillion national debt is ‘not unsustainable,’ but warns the trajectory ‘will not end well’placeholder alt text
By Fortune EditorsMarch 30, 2026
Success
Two-thirds of parents say their adult Gen Z kids still rely on them financially  for support—even though it's putting them under strainplaceholder alt text
By Fortune EditorsMarch 31, 2026
Personal Finance
Kevin O'Leary says if you earn $68,000 a year and follow this rule, you'll retire a millionaireplaceholder alt text
By Fortune EditorsMarch 31, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.